Ocuphire Pharma Results

Oral Treatments in Clinical Development (DR) Most Drugs Target Only Inflammation Company Lilly Ocuphire PHARMA B BAYER R OALKAHESTⓇ Roche Boehringer Ingelheim InflammX Valo REZOLUTE Drug LY333531 APX3330 BAY1101042 AKST4290 RG7774 BI 1467335 HCB 1019 (Xiflam) OPL-0401 RZ402 Company websites; www.clinicaltrials.gov Ocuphire Most Drugs Target Only Inflammation PHARMA Target/MOA Protein Kinase C inhibitor Ref-1 inhibitor (Anti-VEGF and Anti- inflammatory) Guanylate Cyclase activator CCR3 Eotaxin inhibitor CB2 receptor (cannabinoid) AOC3 Connexin 43 (inflammasome) ROCK 1/2 inhibitor Plasma Kallikrein Indication DR DR DR DR DR DR DR DR DME Route of Administration Oral ✓ Completed Oral Oral Oral Oral Oral Oral Oral Oral Phase 1 Phase 2 Phase 3 X 2006 ✓ O X 2021 ⒸOngoing X Discontinued or Failed study 28

View entire presentation